Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2025)
Historic Cash & Equivalents for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $38.3 million.
- Inhibikase Therapeutics' Cash & Equivalents rose 408971.62% to $38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.3 million, marking a year-over-year increase of 408971.62%. This contributed to the annual value of $56.5 million for FY2024, which is 51636.09% up from last year.
- Latest data reveals that Inhibikase Therapeutics reported Cash & Equivalents of $38.3 million as of Q3 2025, which was up 408971.62% from $77.7 million recorded in Q2 2025.
- Over the past 5 years, Inhibikase Therapeutics' Cash & Equivalents peaked at $77.7 million during Q2 2025, and registered a low of $913420.0 during Q3 2024.
- Moreover, its 5-year median value for Cash & Equivalents was $14.9 million (2023), whereas its average is $26.6 million.
- Per our database at Business Quant, Inhibikase Therapeutics' Cash & Equivalents surged by 60152563.9% in 2021 and then tumbled by 9408.58% in 2023.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' Cash & Equivalents stood at $40.8 million in 2021, then tumbled by 82.36% to $7.2 million in 2022, then rose by 27.5% to $9.2 million in 2023, then soared by 516.36% to $56.5 million in 2024, then plummeted by 32.25% to $38.3 million in 2025.
- Its last three reported values are $38.3 million in Q3 2025, $77.7 million for Q2 2025, and $73.4 million during Q1 2025.